Enterolactone is differently associated with estrogen receptor β-negative and -positive breast cancer in a Swedish nested case-control study

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 11, 2008, Pages 3241-3251

  Sonestedt, Emily ^a   Borgquist, Signe ^b   Ericson, Ulrika ^a   Gullberg, Bo ^a   Olsson, Håkan ^c   Adlercreutz, Herman ^d   Landberg, Göran ^b   Wirfält, Elisabet ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROLACTONE; ESTROGEN RECEPTOR BETA;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DIETARY FIBER; FEMALE; FLUOROIMMUNOASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; SMOKING; TISSUE MICROARRAY;

4-BUTYROLACTONE; ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIET; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; LIGNANS; LINEAR MODELS; MICROARRAY ANALYSIS; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SMOKING; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 55849089067     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0393     Document Type: Article

References (60)

1. Mattisson I, Wirfalt E, Johansson U, et al. Intakes of plant foods, fibre and fat and risk of breast cancer - a prospective study in the Malmo Diet and Cancer cohort. Br J Cancer 2004;90:122-7.
2. Milder IE, Arts IC, van de Putte B, Venema DP, Hollman PC. Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr 2005;93:393-402.
3. Mazur W. Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 1998;12:729-42.
4. Heinonen S, Nurmi T, Liukkonen K, et al. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 2001;49:3178-86.
5. Adlercreutz H. Lignans and human health. Crit Rev Clin Lab Sci 2007;44:483-525.
6. Low YL, Dunning AM, Dowsett M, et al. Phytoestrogen exposure is associated with circulating sex hormone levels in postmenopausal women and interact with ESR1 and NR1I2 gene variants. Cancer Epidemiol Biomarkers Prev 2007;16:1009-16.
7. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005;94:461-7.
8. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-63.
9. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites showdistinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004;80:14-25.
10. Penttinen P, Jaehrling J, Damdimopoulos AE, et al. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 2007;148:4875-86.
11. Prasad K. Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol 2000;9:220-5.
12. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997;350:990-4.
13. Pietinen P, Stumpf K, Mannisto S, et al. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Cancer Epidemiol Biomarkers Prev 2001;10:339-44.
14. Olsen A, Knudsen KE, Thomsen BL, et al. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2004;13:2084-9.
15. Hulten K, Winkvist A, Lenner P, et al. An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 2002;41:168-76.
16. Kilkkinen A, Virtamo J, Vartiainen E, et al. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study. Int J Cancer 2004;108:277-80.
17. den Tonkelaar I, Keinan-Boker L, Veer PV, et al. Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:223-8.
18. Verheus M, van Gils CH, Keinan-Boker L, et al. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007;25:648-55.
19. Grace PB, Taylor JI, Low YL, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev 2004;13:698-708.
20. Ward HA, Chapelais G, Kuhnle GG, et al. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the EPIC-Norfolk study. Breast Cancer Res 2008;10:R32.
21. Lampe JW. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 2003;133 Suppl 3:956-64S.
22. Horner NK, Kristal AR, Prunty J, et al. Dietary determinants of plasma enterolactone. Cancer Epidemiol Biomarkers Prev 2002;11:121-6.
23. Kilkkinen A, Stumpf K, Pietinen P, et al. Determinants of serum enterolactone concentration. Am J Clin Nutr 2001;73:1094-100.
24. Johnsen NF, Hausner H, Olsen A, et al. Intake of whole grains and vegetables determines the plasma enterolactone concentration of Danish women. J Nutr 2004;134:2691-7.
25. Milder IE, Kuijsten A, Arts IC, et al. Relation between plasma enterodiol and enterolactone and dietary intake of lignans in a Dutch endoscopy-based population. J Nutr 2007;137:1266-71.
26. Kilkkinen A, Pietinen P, Klaukka T, et al. Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 2002;155:472-7.
27. Riboli E, Elmstahl S, Saracci R, Gullberg B, Lindgarde F. The Malmo Food Study: validity of two dietary assessment methods for measuring nutrient intake. Int J Epidemiol 1997;26 Suppl 1:S161-73.
28. Elmstahl S, Riboli E, Lindgarde F, Gullberg B, Saracci R. The Malmo Food Study: the relative validity of a modified diet history method and an extensive food frequency questionnaire for measuring food intake. Eur J Clin Nutr 1996;50:143-51.
29. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004;15:193-7.
30. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
31. Kushi LH, Potter JD, Bostick RM, et al. Dietary fat and risk of breast cancer according to hormone receptor status. Cancer Epidemiol Biomarkers Prev 1995;4:11-9.
32. Suzuki R, Ye W, Rylander-Rudqvist T, et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst 2005;97:1601-8.
33. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
34. Murphy LC, Watson PH. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 2006;13:327-34.
35. Borgquist S, Holm C, Stendahl M, et al. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 2008;61:197-203.
36. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 2005;56 Suppl 1:21-6.
37. Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006;43:325-47.
38. Manjer J, Carlsson S, Elmstahl S, et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001;10:489-99.
39. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993;233:45-51.
40. Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 1999;59:5425-8.
41. Pero RW, Olsson A, Berglund G, et al. The Malmo biological bank. J Intern Med 1993;233:63-7.
42. Pero RW, Olsson A, Bryngelsson C, et al. Quality control program for storage of biologically banked blood specimens in the Malmo Diet and Cancer Study. Cancer Epidemiol Biomarkers Prev 1998;7:803-8.
43. Adlercreutz H, Wang GJ, Lapcik O, et al. Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 1998;265:208-15.
44. Stumpf K, Uehara M, Nurmi T, Adlercreutz H. Changes in the time-resolved fluoroimmunoassay of plasma enterolactone. Anal Biochem 2000;284:153-7.
45. Sonestedt E, Ericson U, Gullberg B, et al. Variation in fasting and non-fasting serum enterolactone concentrations in women of the Malmo Diet and Cancer cohort. Eur J Clin Nutr 2008;62:1005-9.
46. Callmer E, Riboli E, Saracci R, Akesson B, Lindgarde F. Dietary assessment methods evaluated in the Malmo food study. J Intern Med 1993;233:53-7.
47. Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 2006;100:1171-85.
48. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Geneva (Switzerland): WHO; 2000.
49. Merlo J, Berglund G, Wirfalt E, et al. Self-administered questionnaire compared with a personal diary for assessment of current use of hormone therapy: an analysis of 16,060 women. Am J Epidemiol 2000;152:788-92.
50. Wirfalt E, Mattisson I, Johansson U, et al. A methodological report from the Malmo Diet and Cancer study: development and evaluation of altered routines in dietary data processing. Nutr J 2002;1:3.
51. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002;155:176-84.
52. White E. Effects of biomarker measurement error on epidemiological studies. In: Toniolo P, editor. Application of biomarkers in Cancer Epidemiology 142. Lyon: IARC Scientific Publications; 1997. p. 73-93.
53. Bowey E, Adlercreutz H, Rowland I. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol 2003;41:631-6.
54. Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, Toniolo P. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 1998;7:885-9.
55. Suzuki R, Rylander-Rudqvist T, Saji S, et al. Dietary lignans and postmenopausal breast cancer risk by oestrogen receptor status: a prospective cohort study of Swedish women. Br J Cancer 2008;98:636-40.
56. Touillaud MS, Thiebaut AC, Fournier A, et al. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 2007;99:475-86.
57. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
58. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8.
59. Skliris GP, Parkes AT, Limer JL, et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 2002;197:155-62.
60. Lin CY, Strom A, Li Kong S, et al. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 2007;9:R25.